Survey: The 2022 State of Digital Transformation in Biopharma

Insights from the 2022 State of Digital Lab Transformation Industry Survey

TetraScience teamed up with Pharma IQ to survey biopharma industry insiders and ask about their organizations’ strategies for cloud adoption, digital labs, FAIR data, and the use of artificial intelligence and machine learning (AI/ML).

The 2022 State of Digital Lab Transformation in Biopharma Report shows the importance of digitalization in the pharmaceutical industry and makes a strong case for cloud data platform automation. Industry leaders identify this move as critical in order to improve scientific outcomes and accelerate discovery.

Key findings include:

87% of survey respondents claim that maintaining point-to-point, DIY integrations is burdensome.
74% of biopharma organizations are replatforming their scientific data to the cloud to enable scale, resilience, and faster time to market.
49% of bench scientists' time is spent on manual data retrieval, cleansing, and transformation.

Basic data-to-cloud replatforming is accelerating, but life sciences organizations still face obstacles. About half of the respondents of our survey say that “less than half” or “none” of their data can now be considered FAIR.

Accelerate Digital Transformation in Biopharma

A cloud-based scientific data platform can enable life sciences organizations to speed lab digitization, provide FAIR data to accelerate research and scientific outcomes– adapting to their changing business needs. Download our full report and discover why these initiatives of data automation in the cloud are gaining momentum in biopharma.